Message from Prof. Murali Sastry, CEO:
“It is with immense pleasure and pride that I inform all of you that the first startup from the Academy, Convalesce, has been selected for the Acceleration Program of IndieBio this summer 2018. IndieBio is the world’s leading life science accelerator based in San Francisco providing the best support silicon valley can offer to core biotech startups. IndieBio is backed by the venture SOSV.
Each team receives $250,000 in seed funding, lab and co-working space, dedicated mentorship, and becomes part of a huge network of IndieBio alumni, investors, biotech entrepreneurs, investors, press, corporate partners, and more. Founders engage with customers and partners, pitch to investors, and turn science into a real product people pay for.
Twice a year, IndieBio typically accepts 15 startups worldwide for their acceleration program, which lasts approximately 4 months. The aim is to close the distance between science and money.
As you all know, Subhadeep Das, an alumnus of the Academy, is the brains, heart and soul behind this startup and has pursued the dream of being an entrepreneur with single minded dedication. I am personally of the opinion that the future of Indian business and indeed, science and innovation, will be driven by startups such as Convalesce. This is a moment to be cherished by us all and marks an important milestone in the journey of the Academy. Such achievements in technology, science and business will determine what impact the IITB-Monash Research Academy has not just in India and Australia but globally.
Subhadeep – on behalf of the entire Academy, please accept my warmest congratulations, and best wishes in translating your dreams into reality”.